Last year, Kenvue seemed to be in the clear over claims its popular Tylenol pain medicine caused autism. A federal judge in New York had dismissed thousands of lawsuits after ruling the evidence of plaintiff experts was unreliable. Kenvue shares rose 30% to more than $24 a share, giving the consumer-products company its highest market […]. Read More in Israel NOWlej.
